Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Syntenin inhibition impairs stroma-tumor communication in Multiple Myeloma and improves Bortezomib treatment efficiency

ABSTRACT: In multiple myeloma, the objective is to assess the impact of syntenin knockout on the secretory profile of bone marrow stromal cells using the HS-5 model.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Cell

DISEASE(S): Multiple Myeloma

SUBMITTER: AUDEBERT Stephane

LAB HEAD: Audebert Stéphane, PhD

PROVIDER: PXD064458 | Pride | 2025-07-26

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ContaminantsPrefixHaoLab2022_DiaNNV2.fasta	Fasta
	HS5_KoSynt_A.raw	Raw
	HS5_KoSynt_A_20250427050326.raw	Raw
	HS5_KoSynt_B.raw	Raw
	HS5_KoSynt_B_20250427112435.raw	Raw

Items per page:

1 - 5 of 25

Publications

Syntenin inhibition impairs stroma-tumor communication in multiple myeloma and improves bortezomib treatment efficiency.

Tu Chenggong C Leblanc Raphael R Van der Vreken Arne A Koops Marnix M Audebert Stephane S Goullieux Lauriane L Meeussen Sofie S De Veirman Kim K De Bruyne Elke E Vanderkerken Karin K David Guido G Cupedo Tom T Zimmermann Pascale P Menu Eline E

HemaSphere 20250818 8

Multiple myeloma (MM) remains incurable due to the development of drug resistance. We previously showed that communication between bone marrow stromal cells (BMSCs) and MM cells supports MM growth and triggers therapy resistance. This communication occurs through a plethora of mechanisms, including the release of cytokines and small extracellular vesicles (sEVs). The PDZ protein syntenin is a master regulator of intercellular communication, in particular via sEVs. In this study, we aimed to expl ...[more]

PMID: 40832015

Similar Datasets

Identification of DDX6 ubiquitylated lysines in cAMP-stimulated cells. stimulation

Project description:DDX6 is an RNA helicase mostly located in the P-bodies, membrane-less organelles that play a fundamental role in the post-transcriptional regulation of gene expression. We found that stimulation of the G protein-coupled receptor (GPCR)-cAMP pathway induces a non-proteolytic polyubiquitylation of DDX6 mediated by the RING E3 ligase Praja2. To identify potential lysine residues of DDX6 accepting ubiquitin moieties mediated by Praja2, we performed a proteomic analysis on DDX6 purified from total lysates from cells treated with Forskolin, a diterpene that raises cAMP levels. The analysis identified K26 and K286 as ubiquitylated sites upon cAMP stimulation.

2025-05-26 | PXD054750 | Pride

- Pharmacological inhibition of deoxyhypusine synthase with GC7 in three PCa cell lines (LNCaP and DU145)

Project description:Protein synthesis plays a central role in cancer development and progression. eIF5A (eukaryotic initiation factor 5A), a translation factor activated by hypusination, is implicated in tumorigenesis, however, its mode of action is still unclear. Hypusinated eIF5A (eIF5Ahyp) promotes metastasis and tumor growth in prostate cancer (PCa) by supporting mitochondrial metabolism and translation. To characterize the pro-tumorigenic role of eiF5Ahyp in PCa, we employed pharmacological inhibition of deoxyhypusine synthase (DHPS) with GC7 in two PCa cell lines (LNCaP and DU145) coupled with quantitative proteomics.

2026-01-30 | PXD058627 | Pride

Cyclophostin and Cyclipostins analogues counteract macrolide-induced resistance mediated by Erm(41) in Mycobacterium abscessus

Project description:Mycobacterium abscessus is an emerging pathogen causing severe pulmonary infections, particularly in individuals with underlying conditions, such as cystic fibrosis or chronic obstructive pulmonary disease. Macrolides, including clarithromycin (CLR) and azithromycin (AZM), represent the current cornerstone of antibiotherapy against M. abscessus complex. However, prolonged exposure to macrolides can induce the apparition of Erm(41)-mediated resistance, limiting their spectrum of activity and often leading to therapeutic failure. Therefore, inhibiting Erm(41) could thwart this resistance mechanism to maintain macrolide susceptibility and avoid the therapeutic failure. In a previous study, the Erm(41) methyltransferase was identified as a target enzyme of Cyclipostins and Cyclophostin compounds (CyC). Herein, we took advantage of this feature to evaluate the in vitro activity of clarithromycin and azithromycin in combination with different CyC via the checkerboard assay on macrolide susceptible and induced macrolide-resistant M. abscessus generated by either clarithromycin or azithromycin exposure. Our results emphasize the use of the CyC to prevent/overcome Erm(41) induced resistance, restore macrolide susceptibility. This work should help to expand our therapeutic arsenal in the fight against a particularly antibiotic resistant mycobacterial species and could provide the opportunity to revisit the therapeutic regimen for combating M. abscessus pulmonary infections in CF patients, and particularly in erm(41)-positive strains.

2024-12-05 | PXD055560 | Pride

Deciphering the dynamic proteome of multiciliated cells

Project description:Multiciliated cells (MCCs) are essential for generating directional fluid flow across specialized epithelia in various vertebrate organs. MCC differentiation involves a unique, tightly regulated program characterized by massive centriole amplification, independently of DNA replication. Although much is known about the transcriptional control of MCC development, insights into proteome dynamics have been limited due to the lack of suitable models. In this study, we report the generation of a stable inducible MCC line, derived from Xenopus laevis A6 kidney epithelial cells. Upon induction of the MCC master regulator Multicilin (MCI), most A6-MCI cells synchronously differentiate into mature MCCs in 48 hours. Using this novel resource, custom antibodies and super-resolution imaging, we could characterize Xenopus deuterosomes, the platforms that allow massive centriole synthesis in vertebrate MCCs. We performed a detailed proteomic profiling throughout MCC differentiation, and uncovered previously uncharacterized regulators. Notably, we highlight a critical role for CDK7 in MCC differentiation in both Xenopus and human systems. Our work provides a valuable resource for mechanistic studies of MCC biology and opens avenues to identify novel therapeutic targets for motile ciliopathies.

2026-02-06 | PXD064476 | Pride

Combining laser capture micro-dissection and proteomics reveals an active translation machinery controlling invadosome formation

Project description:We developed a method that combines laser micro-dissection and mass spectrometry, enabling the analysis of subcellular structures in their native state based on low amounts of input material. Using this combinatorial method, we showed that invadosomes contain specific components of the translational machinery, in addition to known marker proteins.

2018-10-19 | PXD009390 | Pride

Phosphorylation of claudin-11 - Mass spectrometry analysis confirmed the phosphorylation of human claudin-11 at tyrosine 191 and tyrosine 192

Project description:Mass spectrometry analysis confirmed the phosphorylation of human claudin-11 at tyrosine 191 and tyrosine 192

2018-08-29 | PXD010908 | Pride

Cyclipostins and Cyclophostin analogs impair growth of Mycobacterium abscessus by inhibiting enzymes involved in many physiological processes

Project description:Mycobacterium abscessus is nowadays under the spotlight of the scientific community. This pathogenic mycobacteria is indeed responsible for a wide spectrum of infections involving mostly pulmonary infections in patients with cystic fibrosis. M. abscessus is intrinsically resistant to a broad range of antibiotics, including most antitubercular drugs, and is considered the most pathogenic and chemotherapy-resistant rapidly growing mycobacterium. Consequently, with very limited treatment options, the development of new therapeutic approaches to fight this pathogen are urgently needed. 38 new analogs of Cyclipostins & Cyclophostin (CyC), compounds naturally produced by Streptomyces species, have been synthesized. Their antibacterial activities against clinical isolates belonging to the M. chelonae-abscessus clade, as well as Gram-negative and Gram-positive bacteria have been evaluated by the REMA method. The intracellular activities of the CyC against intramacrophagic M. abscessus have also been investigated and compared to those of imipenem. The CyCs displayed very low toxicity towards host cells and their inhibitory activity was exclusively restricted to mycobacteria. The best candidate, CyC17, showed a high selectivity for mycobacteria with MIC values (<2 up to 40 µg/mL) comparable to those of most classical antibiotics used to treat M. abscessus infections. Of importance, several CyCs were active against extracellular M. abscessus growth (i.e., CyC17 / CyC18β / CyC25 / CyC26) or against intracellular mycobacteria inside macrophages (i.e., CyC7α,β / CyC8α,β) with MIC values similar to or better than those of standard antibiotics. Based on these results, we intended to identify the potential target enzymes of CyC17/CyC26 in M. abscessus by activity-based protein profiling (ABPP) approach coupled with mass spectrometry differential analysis.

2019-10-08 | PXD014255 | Pride

Dissecting the antibacterial activity of Oxadiazolone-core derivatives against Mycobacterium abscessus

Project description:Mycobacterium abscessus is nowadays under the spotlight of the scientific community. This pathogenic mycobacteria is indeed responsible for a wide spectrum of infections involving mostly pulmonary infections in patients with cystic fibrosis. M. abscessus is intrinsically resistant to a broad range of antibiotics, including most antitubercular drugs, and is considered the most pathogenic and chemotherapy-resistant rapidly growing mycobacterium. Consequently, with very limited treatment options, the development of new therapeutic approaches to fight this pathogen are urgently needed. In this context, 19 oxadiazolone (OX) derivatives have been investigated for their antibacterial activity against both the rough (R) and smooth (S) variants of M. abscessus. Several OXs were active against extracellular M. abscessus growth with moderated minimal inhibitory concentrations (MIC), or intracellularly by inhibiting M. abscessus growth inside infected macrophages with MIC values similar to those of imipenem. Such promising results prompted us to identify the potential target enzymes of the sole extra and intracellular inhibitor of M. abscessus growth, i.e., iBpPPOX via activity-based protein profiling combined with mass spectrometry. This approach led to the identification of 21 potential protein candidates being mostly involved in M. abscessus lipid metabolism and/or in cell wall biosynthesis.

2020-08-14 | PXD015680 | Pride

Interactomics of the RLTPR protein explain its essential role for costimulation via CD28

Project description:The RLTPR cytosolic protein has an essential role in CD28 costimulation but its mode of action and importance in human T cells remain elusive. Here, using mass spectrometry we showed that CD28, RLTPR and the CARMA1 cytosolic adaptor physically associate in mouse T cells. Although RLTPR is thought to function as an actin-uncapping protein, this property was dispensable for CD28 costimulation. Our findings underpin the convergent function of RLTPR in T cells and suggest that its scaffolding role predominates during CD28 costimulation.

2016-09-27 | PXD003870 | Pride

Widespread multi-targeted therapy resistance via drug-induced secretome fucosylation

Project description:Cancer secretome is a reservoir for aberrant glycosylation. How therapies alter this post translational cancer hallmark and the consequences thereof remain elusive. Here we show that an elevated secretome fucosylation is a pan-cancer signature of both response and resistance to multiple targeted therapies. Large-scale pharmacogenomics revealed that fucosylation genes display widespread association with resistance to these therapies. In both cancer cell cultures and patients, targeted kinase inhibitors distinctively induced core fucosylation of secreted proteins less than 60 kDa. Label-free proteomics of N-glycomes revealed that fucosylation of the antioxidant PON1 is a critical component of the therapy induced secretome. Core fucosylation in the Golgi impacts PON1 stability and folding prior to secretion, promoting a more degradation-resistant PON1. Non-specific and PON1-specific secretome deglycosylation both limited the expansion of resistant clones in a tumor regression model. Our findings demonstrate that core fucosylation is a common modification indirectly induced by targeted therapies that paradoxically promotes resistance

2023-04-05 | PXD022240 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data